KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $250.6 million.

  • Vertex Pharmaceuticals' Other Working Capital Changes rose 5224.79% to $250.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $396.0 million, marking a year-over-year increase of 9770.34%. This contributed to the annual value of $396.0 million for FY2025, which is 9770.34% up from last year.
  • According to the latest figures from Q4 2025, Vertex Pharmaceuticals' Other Working Capital Changes is $250.6 million, which was up 5224.79% from $40.9 million recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Other Working Capital Changes registered a high of $451.3 million during Q4 2023, and its lowest value of -$99.2 million during Q1 2024.
  • Moreover, its 5-year median value for Other Working Capital Changes was $34.5 million (2025), whereas its average is $78.0 million.
  • Examining YoY changes over the last 5 years, Vertex Pharmaceuticals' Other Working Capital Changes showed a top increase of 188930.82% in 2022 and a maximum decrease of 60827.07% in 2022.
  • Over the past 5 years, Vertex Pharmaceuticals' Other Working Capital Changes (Quarter) stood at -$15.9 million in 2021, then surged by 1889.31% to $284.5 million in 2022, then skyrocketed by 58.63% to $451.3 million in 2023, then crashed by 63.53% to $164.6 million in 2024, then surged by 52.25% to $250.6 million in 2025.
  • Its last three reported values are $250.6 million in Q4 2025, $40.9 million for Q3 2025, and $76.4 million during Q2 2025.